Bausch Health Extends DURECT Tender Offer Deadline

Bausch Health Companies Inc. has announced the extension of its tender offer to acquire all outstanding shares of DURECT Corporation. The offer now expires on September 10, 2025, a day later than initially planned. This action involves a cash transaction valued at $1.75 per share, totaling around $63 million, with potential milestone payments reaching $350 million.

The offer is contingent on specific conditions, including the majority tendering of DURECT's shares. It aligns with terms detailed in the "Offer to Purchase" document filed with the U.S. Securities and Exchange Commission. Bausch Health emphasizes that holders who've previously tendered shares are not required to retender.

The extension reflects Bausch Health's strategic maneuvering as it aims to consolidate its position within the pharmaceutical sector.